Cisplatin in triple negative breast cancer
| Author | n | Setting | Regimen | Efficacy |
|---|---|---|---|---|
| Garber et al.31 | 28 | Neoadjuvant | Cisplatin | pCR rate: 22% |
| Ezzat et al.32 | 126 | Neoadjuvant | Cisplatin/ paclitaxel | pCR rate: 28% |
| Frasci et al.33 | 74 | Neoadjuvant | Cisplatin/epirubicin/paclitaxel | pCR rate: 65% |
| Byrski et al.55 | 20 | Metastatic | Cisplatin or carboplatin | cCR rate: 45% |
| Kilburn et al.56 | 400 | Metastatic | Carboplatin or docetaxel | 15% improvement in carboplatin |
| Carey et al.75 | 102 | Metastatic | Carboplatin + cetuximab | RR: 18% |